Shares of Kura Oncology, Inc. (KURA) have traded between $12.65 – 21.42. The next earnings date is set for Mar 03, 2020. Let’s see how its prospects are shaping up.
What does Kura Oncology, Inc.(KURA) do?
Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia; KO-947 which is an ERK inhibitor for MAPK Pathway Tumors; and KO-539 which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in La Jolla, CA.
KURA Insider Trading Insight
On 2019-07-10, Gualberto Antonio Head of Development, CMO sold 18,000 shares of KURA. That represents a value of $339,973. Not to be outdone, on 2018-12-17, Ecor1 Capital Fund Qualified, L.P. S – Sale sold26,520 shares of KURA. These insiders are clearly in the know because they work closely with the company.
The NSP Consensus Price Target
The mean recommendation of Insperity, Inc. from top Wall Street analysts is a Moderate Buy. That is based on 1 analysts who work on the Street. Based on 1 analyst offering 12 month price targets for Insperity in the last 3 months. The average price target is $128.00 with a high forecast of $128.00 and a low forecast of $128.00. The average price target represents a 40.95% increase from the last price of $90.81. Last week, several articles were published in financial papers about NSP and 37% Bearish while 63% Bullish.
NSP Intraday Trading
NSP is due to report earnings on Feb 10, 2020. In the last year the price has ranged from 67.06 – 144.92. Recently, Mincks Jay E sold 2.000 shares of NSP. He is a $ 168,000 shareholder in NSP.
Looking for stocks similar to KURA and NSP?